TY - JOUR
T1 - Quantitative genome-scale metabolic modeling of human CD4+ T cell differentiation reveals subset-specific regulation of glycosphingolipid pathways
AU - Sen, Partho
AU - Andrabi, Syed Bilal Ahmad
AU - Buchacher, Tanja
AU - Khan, Mohd Moin
AU - Kalim, Ubaid Ullah
AU - Lindeman, Tuomas Mikael
AU - Alves, Marina Amaral
AU - Hinkkanen, Victoria
AU - Kemppainen, Esko
AU - Dickens, Alex M.
AU - Rasool, Omid
AU - Hyötyläinen, Tuulia
AU - Lahesmaa, Riitta
AU - Orešič, Matej
N1 - Funding Information:
We thank Marjo Hakkarinen and Sarita Heinonen (Turku Bioscience Center, University of Turku, Turku, Finland) for excellent technical assistance. We would like to acknowledge the Turku Metabolomics Centre and Biocenter Finland for their contribution to metabolomic analysis. We thank Dr. Aidan McGlinchey (School of Medical Sciences, ?rebro University, ?rebro, Sweden) for assistance with editing the manuscript. This study was supported by the Novo Nordisk Foundation (NNF18OC0034506 and NNF19OC0057418 to M.O.), the Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (SyMMyS) (no. 250114 to M.O. and R.L.), the Academy of Finland (no. 333981 to M.O. and nos. 292335, 294337, and 319280 to R.L.), the Sigrid Jus?lius Foundation (to R.L.), the Jane and Aatos Erkko Foundation (to R.L.), the Finnish Cancer Foundation (to R.L.), and the Juvenile Diabetes Research Foundation (2-SRA-2014-159-Q-R to M.O). M.O. proposed the study. R.L. and M.O. supervised the study. P.S. U.U. R.L. and M.O. assisted with the formulation of study design. P.S. performed GSMM and analyzed the multi-omics datasets. T.H. and A.D. supervised the metabolomics experiments. T.L. M.A. A.M.D. and T.H. acquired the metabolomics data. E.K. V.H. S.B.A.A. T.B. M.M.K. and O.R. prepared and provided CD4+ T cell subsets for metabolomics experiments. S.B.A.A. and T.B. performed the siRNA knockdown experiments. P.S. and M.O. wrote the manuscript. All authors critically reviewed and approved the final manuscript. M.O. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors declare no competing interests.
Funding Information:
We thank Marjo Hakkarinen and Sarita Heinonen (Turku Bioscience Center, University of Turku, Turku, Finland) for excellent technical assistance. We would like to acknowledge the Turku Metabolomics Centre and Biocenter Finland for their contribution to metabolomic analysis. We thank Dr. Aidan McGlinchey (School of Medical Sciences, Örebro University, Örebro, Sweden) for assistance with editing the manuscript. This study was supported by the Novo Nordisk Foundation ( NNF18OC0034506 and NNF19OC0057418 to M.O.), the Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (SyMMyS) (no. 250114 to M.O. and R.L.), the Academy of Finland (no. 333981 to M.O. and nos. 292335 , 294337 , and 319280 to R.L.), the Sigrid Jusélius Foundation (to R.L.), the Jane and Aatos Erkko Foundation (to R.L.), the Finnish Cancer Foundation (to R.L.), and the Juvenile Diabetes Research Foundation ( 2-SRA-2014-159-Q-R to M.O).
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/11/9
Y1 - 2021/11/9
N2 - T cell activation, proliferation, and differentiation involve metabolic reprogramming resulting from the interplay of genes, proteins, and metabolites. Here, we aim to understand the metabolic pathways involved in the activation and functional differentiation of human CD4+ T cell subsets (T helper [Th]1, Th2, Th17, and induced regulatory T [iTreg] cells). Here, we combine genome-scale metabolic modeling, gene expression data, and targeted and non-targeted lipidomics experiments, together with in vitro gene knockdown experiments, and show that human CD4+ T cells undergo specific metabolic changes during activation and functional differentiation. In addition, we confirm the importance of ceramide and glycosphingolipid biosynthesis pathways in Th17 differentiation and effector functions. Through in vitro gene knockdown experiments, we substantiate the requirement of serine palmitoyltransferase (SPT), a de novo sphingolipid pathway in the expression of proinflammatory cytokines (interleukin [IL]-17A and IL17F) by Th17 cells. Our findings provide a comprehensive resource for selective manipulation of CD4+ T cells under disease conditions characterized by an imbalance of Th17/natural Treg (nTreg) cells.
AB - T cell activation, proliferation, and differentiation involve metabolic reprogramming resulting from the interplay of genes, proteins, and metabolites. Here, we aim to understand the metabolic pathways involved in the activation and functional differentiation of human CD4+ T cell subsets (T helper [Th]1, Th2, Th17, and induced regulatory T [iTreg] cells). Here, we combine genome-scale metabolic modeling, gene expression data, and targeted and non-targeted lipidomics experiments, together with in vitro gene knockdown experiments, and show that human CD4+ T cells undergo specific metabolic changes during activation and functional differentiation. In addition, we confirm the importance of ceramide and glycosphingolipid biosynthesis pathways in Th17 differentiation and effector functions. Through in vitro gene knockdown experiments, we substantiate the requirement of serine palmitoyltransferase (SPT), a de novo sphingolipid pathway in the expression of proinflammatory cytokines (interleukin [IL]-17A and IL17F) by Th17 cells. Our findings provide a comprehensive resource for selective manipulation of CD4+ T cells under disease conditions characterized by an imbalance of Th17/natural Treg (nTreg) cells.
KW - CD4 T cells
KW - ceramides
KW - gene expression
KW - genome-scale metabolic modeling
KW - glycosphingolipid metabolism
KW - lipid metabolism
KW - lipidomics
KW - metabolic pathways
KW - sphingolipids
KW - type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85118862025&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2021.109973
DO - 10.1016/j.celrep.2021.109973
M3 - Article
C2 - 34758307
AN - SCOPUS:85118862025
SN - 2211-1247
VL - 37
JO - Cell Reports
JF - Cell Reports
IS - 6
M1 - 109973
ER -